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Abstract: Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide.
Although most of the primary CRC can be removed by surgical resection, advanced tumors sometimes
show recurrences in distant organs such as the liver, lung, lymph node, bone or peritoneum even
after complete resection of the primary tumors. In these advanced and metastatic CRC, it is the
tumor-stroma interaction in the tumor microenvironment that often promotes cancer invasion and/or
metastasis through chemokine signaling. The tumor microenvironment contains numerous host
cells that may suppress or promote cancer aggressiveness. Several types of host-derived myeloid
cells reside in the tumor microenvironment, and the recruitment of them is under the control of
chemokine signaling. In this review, we focus on the functions of chemokine signaling that may affect
tumor immunity by recruiting several types of bone marrow-derived cells (BMDC) to the tumor
microenvironment of CRC.
Keywords: colon cancer; tumor microenvironment; myeloid cells; cancer immunity
1. Introduction
Although primary colorectal cancer (CRC) can be cured by surgical resection if without metastases,
the patient survival rate worsens once it metastasizes to vital organs such as the liver or lungs.
Primary CRC develops progressively through accumulation of genetic mutations in such genes as APC,
KRAS, p53, SMAD4 and PTEN, and epigenetic silencing of tumor suppressor genes [1,2]. In addition
to these genetic and epigenetic alterations, there is mounting evidence that CRC accumulates invasive
and metastatic capacities through tumor-stroma interactions, the so-called tumor microenvironment.
Moreover, several further reports indicate that the tumor microenvironment not only promotes cancer
invasion and metastasis but also provides resistance to chemotherapy [3]. Therefore, it is imperative to
understand the tumor microenvironment thoroughly in order to achieve a comprehensive therapy,
especially against advanced and metastatic CRC.
Chemokines are small peptides that are structurally and functionally similar to growth factors,
binding to G-protein-coupled receptors to induce chemoattraction, inflammation and/or angiogenesis.
They are also one of the key players that promote cancer cell metastasis in some types of cancers [4].
The tropism of metastatic cancer cells for specific organs can be aided by interactions between
chemokine receptors on cancer cells and their respective ligands in the target organs. The role
of chemokine receptors in metastatic organ selectivity was first reported for CXCR4, a receptor that
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stimulates metastasis of breast cancer and melanoma cells to the lung and lymph node where its ligand,
CXCL12 (also known as SDF-1: stromal cell-derived factor 1), is abundant [5]. Furthermore, recent
studies have suggested that chemokines are produced by cancer cells, leading to the recruitment of host
cells into the tumor microenvironment. Several types of host cells interact with tumor epithelial cells in
the tumor microenvironment and promote invasion and metastasis [6]. For example, cancer-associated
fibroblasts (CAF) stimulate the growth of breast cancer cells through secretion of CXCL12 [7].
Mesenchymal stem cells (MSC) also play a role in breast cancer metastasis through secretion of
CCL5 [8]. Recently, it has become increasingly evident that bone marrow-derived cells (BMDC)
contribute to malignant progression has been increasingly evident [6,9–12]. Various mouse models have
shown that BMDC play important roles in tumor progression: tumor-associated macrophages (TAM),
myeloid-derived suppressor cells (MDSC) and tumor-associated neutrophils (TAN). However, it
remains to be determined whether similar mechanisms are involved in humans. The best-characterized
among them, TAM, are divided into two populations: M2 TAM that are pro-tumorigenic and M1 TAM
that are anti-tumorigenic. MDSC constitute a heterogeneous population of immature myeloid cells
that increase in number in cancer, inflammation and infection [13]. Human MDSC lack expression of
conventional cellular markers for T cells, B cells, natural killer (NK) cells and macrophages, whereas
they are positive for the common myeloid cell markers CD33 and CD11b, while negative for the human
leukocyte antigen D-related (HLA-DR). MDSC can inhibit T cell reaction, antibody production and
cytotoxic T lymphocyte (CTL) induction. They are comprised of two subpopulations; monocytic-MDSC
(HLA-DR´, CD11b+, CD33+ and CD14+) and granulocytic-MDSC (HLA-DR´, CD11b+, CD33+ and
CD15+) [14]. TAN also have differential states of activation and differentiation as similarly defined
with M1 and M2 TAM: N1 TAN are anti-tumorigenic, whereas N2 TAN display pro-tumorigenic
properties [15,16]. Several studies show that an elevated neutrophil count in the peripheral blood
(i.e., a high neutrophil-to-lymphocyte ratio [NLR]) is associated with poor clinical outcomes in many
types of cancer including CRC [17], emphasizing the importance and relevance of neutrophils in
cancer biology.
Tumor tissues consist of both cancer epithelial cells and normal stromal cells. In the tumor stroma,
there are several types of host structures as extracellular matrix and cells including vascular endothelial
cells, fibrous tissue cells (e.g., CAF and MSC), and immune cells such as NK cells, dendritic cells (DC),
eosinophils, basophils, mast cells, regulatory T cells (T-reg), tumor infiltrating lymphocytes (TIL),
TAM, TAN and MDSC [18]. Cancer cells induce inflammation through secretion of several cytokines
and chemokines in their invasive process. Dysregulation of tissue homeostasis can cause to extensive
cytokine production, a cytokine burst, allowing cancer cells to survive by hijacking the normal immune
system. Some of them have been elucidated to suppress anti-tumor immunity and promote tumor
expansion in the surrounding stromal tissues.
In this review, we will discuss the roles of several types of BMDC in constructing the metastatic
microenvironment for CRC through chemokine signaling. Accordingly, we list the chemokine
ligand-receptor interactions that are reported so far to be involved in CRC progression by affecting
myeloid cells in the tumor microenvironment (Table 1).
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CRC EC * Angiogenesis [19]
Liver CRC Liver metastasis [20]
Inflamed colon MDSC Colitis-associated tumorigenesis [21]
CXCL9/10–CXCR3
Lymph node CRC Lymph node metastasis [22,23]
CRC Th1 Anti-tumor immunity [24]
CXCL12–CXCR4
Liver CRC Liver metastasis [23,25–28]
EC *, myofibroblast CRC Liver metastasis [29,30]
CRC ND † Shorten OS and RFS [31]
CCL2–CCR2
CRC TAM Disease progression [32,33]
CRC BMDC Liver metastasis [34]
CRC MDSC Carcinogenesis [35]
CRC EC, monocyte Extravasation and metastasis [36]
CCL5–CCR5
CTL CTL, Th1 Anti-tumor immunity [24]
CRC T-reg Tumor growth [37]
CCL15-CCR1
CRC BMDC Invasion and liver metastasis [38–40]
CRC TAN Liver metastasis [41]
CRC MDSC Invasion [42]
CCL20–CCR6 TAM T-reg, Th17 Tumor progression [43]
CCL19–CCR7 DC ¶ CTL Anti-tumor immunity [44,45]
CX3CL1–CX3CR1 ND † TAM Liver metastasis [46]
* EC: endothelial cell; ¶ DC: dendritic cells; † ND: not described.
2. CXCL12 and CXCR4
The CXCL12-CXCR4 axis is one of the representative chemokine signaling involved in cancer
metastasis [5]. Namely, breast cancer cells that express CXCR4 frequently metastasize to the lung,
liver, lymph node and bone marrow where CXCL12 is expressed at high levels. In the liver, one of
the most frequent sites of CRC metastasis, CXCL12 is secreted from the endothelial cells, Kupffer
cells and α-smooth muscle actin (α-SMA)-positive myofibroblasts [29,30]. Fibroblasts often constitute
the majority of the stromal cells, and CAF extracted from invasive human breast cancer promotes
tumor growth and angiogenesis through CXCL12 secretion in a mouse model [7]. Autocrine tumor
growth factor beta (TGF-β) and CXCL12 signaling loops initiate and maintain the differentiation of
fibroblasts into myofibroblasts and the concurrent tumor-promoting phenotype [47]. In CRC, it has
been shown in clinical studies that CXCR4 expression correlates with tumor recurrence, poor survival
and liver metastasis [22,23,25–28]. Expression of CXCR4 in CRC cell lines was also upregulated under
hypoxia by hypoxia-inducible factor 1-alpha (HIF-1α) activity [48]. Its ligand, CXCL12, is also secreted
by CRC cells, but the significance of CXCL12 expression by cancer cells remains controversial so
far. Namely, CXCL12 expression in CRC cells appears to be bidirectional: tumor promotive [31] or
tumor suppressive [49]. Even in the latter case, CXCR4 and CXCL12 were reported to be reciprocally
expressed in CRC [50], indicating that CRC cells always show high-level expression of either CXCL12
or CXCR4, but not both. As a result, we have come to the consensus that pharmacologic inhibition of
the CXCL12–CXCR4 axis may suppress CRC metastasis and prolong the survival period [51,52].
Activation of the CXCL12–CXCR4 axis recruits not only CXCR4+ cancer cells but also CXCR4+
BMDC that promote angiogenesis in a vascular endothelial growth factor (VEGF)-dependent [53] or
-independent [54] manner. The contribution by myeloid BMDC in cancer metastasis was first reported
as a “pre-metastatic niche” mouse model where CD11b+ VEGFR1+ BMDC accumulate at a niche of the
lung before the arrival of cancer cells [55]. In this model, CXCL12 secreted by BMDC attract CXCR4+
tumor cells to the pre-metastatic niche through the CXCL12–CXCR4 axis, aiding lung metastasis.
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It was also reported that VEGFR1 and CXCR4 independently caused a pro-migratory effect on BMDC
through the VEGF–VEGFR1 and CXCL12–CXCR4 pathways, respectively [54]. Recently, a humanized
antibody targeting CXCL12 has been established [56]. Treatment with this antibody dramatically
inhibits distant metastases in multiple xenografts and breast cancer orthotopic models, which may
also bring a significant benefit for the treatment of CRC as well.
3. CXCL9/10 and CXCR3
CXCR3 may provide details of one of the attractive explanations how cancer cells metastasize
to their draining lymph nodes. We earlier reported that CXCR3 expressed on melanoma and CRC
cells promoted their metastases to the draining lymph nodes where CXCL9/10, ligands of CXCR3, are
expressed at high levels [22,23,57,58]. We also found that CRC patients with CXCR3+ tumors showed
significantly shorter survival rates than those without CXCR3, and that CRC patients with tumors
double-positive for both CXCR3 and CXCR4 had a significantly poorer prognosis than those with
tumors positive only for CXCR4 or those that were double-negative [22,58]. It was also reported that
CXCR3 expression was up-regulated in metastatic CRCs compared to their primary counterparts, and
that activation of the CXCL10–CXCR3 axis significantly up-regulated invasion-related properties in
CRC [59]. In addition to CRC, CXCR3 was also reported to be correlated with a poor prognosis in
breast cancer and melanoma [60,61]. Notably, systemic administration of a small molecular inhibitor of
CXCR3 (AMG487) inhibited lung metastasis of CRC as well as breast cancer in murine models [62,63].
In host-targeted investigations, it has been reported recently that deletion of CXCR3 in all host cells
significantly decreased lung metastasis of breast cancer by decreased expression of IL-4, IL-10, inducible
nitric oxide synthase (iNOs) and arginase-1 (Arg1) in myeloid cells with an increased T cell response [64].
CXCL10, ligand for CXCR3, is also secreted by CRC cells, which recruits CXCR3+ helper T
lymphocytes type 1 (Th1) at the invasion front of CRC and contributes to anti-tumor immunity [24].
Expression of CXCL10 in stage II and/or III CRC was reported to be an independent good prognostic
factor regarding recurrence [65,66], whereas another recent study shows that co-expression of CXCL10
and CXCR3 in CRC is a predictor of metastatic recurrence and poor prognosis [67]. The serum
CXCL10 level was reported to be associated with a poor prognosis for CRC patients, as well as a high
malignant status such as high pathological T stage, vascular invasion and distant metastasis [68].
Further comprehensive studies are awaited to assess the significance of CXCL10 expression in CRC.
4. CXCL1/2/5/8 and CXCR2
CXC chemokines with an ELR (Glu-Leu-Arg) motif such as CXCL1, CXCL2, CXCL5 and CXCL8
bind to CXCR2, and promote angiogenesis. The pro-inflammatory lipid mediator prostaglandin E2
(PGE2) plays a critical role in promoting CRC growth through production of VEGF in the stroma, aiding
tumor angiogenesis [69]. PGE2 also stimulates pro-angiogenic chemokine CXCL1 expression in human
CRC cells [19]. CXCL1 released from CRC cells induces CXCR2+ endothelial cell migration, causing
increased tumor microvessel formation. The VEGF-independent angiogenic function of PGE2-derived
CXCL1 may explain the refractoriness of anti-VEGF treatment in CRC patients. Consistently, CXCL1
expression is up-regulated in human CRC specimens compared with the adjacent normal tissues [70].
CXCL1 also contributes to tumor cell transformation, growth and invasion; the knockdown of
CXCL1 in CRC cells causes inhibition of cell viability, resulting in the prevention of tumor growth
in mouse models [71]. By comparing gene signatures of breast cancer cell lines with weak or strong
metastatic tropism for the lung, CXCL1 is one of the gene products that promote lung metastasis [72].
The CXCL1–CXCR2 axis is also important for the formation of the pre-metastatic niche of CRC liver
metastasis, and TSU68, an anti-angiogenic receptor tyrosine kinase inhibitor, suppressed CXCL1
expression in the pre-metastatic liver, resulting in suppression of the homing of CXCR2+ neutrophils
and subsequent liver metastasis in a mouse model [20]. These results strongly suggest that anti-CXCL1
treatment may become an important strategy when used alongside the conventional chemotherapy
with or without anti-VEGF therapy that already is being used worldwide.
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In a breast cancer model (PyMT/Tgfbr2KO mammary carcinoma), a mutated TGF-β receptor
causes recruitment of CD11b+ Gr-1+ MDSC at the tumor invasion front via the CXCL5–CXCR2
and CXCL12–CXCR4 axes, and contributes to tumor invasion and lung metastasis through
metalloproteinase (MMP) secretion [73]. It was also reported that loss of TGF-β signaling promoted
CXCL1 and CXCL5 secretion, which increased migration of CD11b+ Gr-1+ MDSC to the tumor
tissues, and played indirect roles in increasing the number of T helper 17 (Th17) cells which have
a pro-tumorigenic effect [74]. Given the implication of CD11b+ Gr-1+ MDSC in suppressing tumor
immunosurveillance, angiogenesis and tumor invasion, it is possible that targeting the homing or
function of MDSC becomes therapeutically effective. MDSC express chemokine receptors such as
CXCR2 and CCR2 in several types of cancer [21,75]. In a mouse model of colitis-associated CRC, the
levels of CXCR2 ligands were significantly elevated in inflamed colonic mucosa and tumors compared
with in adjacent normal mucosa, and CXCR2+ MDSC accelerated tumor growth by inhibiting CD8+ T
cell cytotoxicity activity [21]. Genetic depletion of Cxcr2 (Cxcr2 knockout mice) diminished massive
infiltration of granulocytic-MDSC into the tumors and retained them in their circulatory system,
reducing chronic colonic inflammation and colitis-associated tumorigenesis. In CRC patients, the
number and proportion of circulating and tumor-infiltrating MDSC were markedly increased compared
with healthy individuals, and these increases were closely correlated with a clinical stage and tumor
metastasis [76]. Tumor signaling through programmed death 1 (PD-1) on T cells and expansion of
MDSC are major mechanisms of tumor immune escape. Notably, prevention of CXCR2-mediated
MDSC trafficking by anti-CXCR2 mAb therapy enhances anti-PD-1 efficacy in a mouse model of
rhabdomyosarcoma, suggesting a translatable strategy to improve the efficacy of immune checkpoint
blockade therapy by preventing trafficking of MDSC to the tumor site [77].
CXCL8 (IL-8) is the first-described angiogenic chemokine with an ELR motif, and is secreted
by CRC cells exposed to pro-inflammatory cytokines such as TNF-α and IL-1α [78]. CXCL8 can be
induced by hypoxia even in HIF-1-deficient CRC cells as a compensatory pathway of VEGF to preserve
tumor angiogenesis, suggesting the potential for combination regimens that target both HIF-1 and
CXCL8 [79]. CXCL8 was also reported to be associated with metastatic potential and a resistance
to oxaliplatin [80]. In mice that express human CXCL8, it contributes to colon carcinogenesis by
increased mobilization of CD11b+ Gr-1+ immature myeloid cells [81]. In Cxcr2 knockout mice, lack of
the CXCL8–CXCR2 axis in the tumor microenvironment prevented CRC growth and metastasis [82].
In addition, small molecule antagonists of CXCR1 and CXCR2 inhibited liver metastasis of CRC by
decreasing tumor angiogenesis and inducing tumor cell apoptosis in a mouse model [83]. Increased
serum CXCL8 concentrations have been associated with distant metastasis and advanced clinical
stages of CRC [80].
5. CCL15 and CCR1
SMAD4 is a transcription factor that plays a pivotal role in TGF-β signaling, and is one of
the tumor suppressors of CRC [84–86]. In a genetically-engineered Apc+/∆716/Smad4+/´ compound
knockout mice that develop invasive intestinal adenocarcinomas [87], mouse CCL9 (mCCL9) is secreted
from the cancer epithelium, which recruits CCR1+ myeloid cells to promote tumor invasion [38].
In a mouse model of liver metastasis, mCCL9-expressing CRC cell lines recruit CCR1+ myeloid cells
to expand metastatic foci in the liver [39], and four distinct types of myeloid cells are found to be
recruited to the liver metastatic foci: CCR1+ neutrophils, eosinophils, monocytes and fibrocytes [41].
Using Ccr1 knockout mice, another group has reported that CCR1 expression by both hematopoietic
and nonhematopoietic cells promotes liver metastasis through myeloid cell accumulation and
angiogenesis [88]. In addition to these mouse models, we have recently reported that SMAD4 binds
directly to the promoter region of human CCL15 gene (a human ortholog of mouse Ccl9) and negatively
regulates its expression [40]. Using human clinical specimens, we have also showed that loss of SMAD4
promotes CCL15 expression from CRC cells to recruit CCR1+ myeloid cells, which facilitates primary
tumor invasion and liver metastasis of CRC [40,42]. Most CCR1+ cells accumulating at the invasion
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front of primary CRC were of the MDSC phenotype (CD11b+, CD33+, and HLA-DR´) [42]. Importantly,
patients with CCL15-expressing CRC in their liver metastases showed significantly shorter relapse-free
survival (RFS) than those with CCL15-negative CRC [40]. Stage II and III patients with CCL15-positive
primary CRC also tended to have shorter RFS than those with CCL15-negative CRC [42]. In addition,
we have found that loss of SMAD4 promotes lung metastasis of CRC by accumulation of CCR1+ TANs
through the CCL15–CCR1 axis, and that CCL15 expression in lung metastases is an independent
predictor of a poorer prognosis in CRC patients (Yamamoto et al. unpublished data). Notably, it has
been reported that activation of the CCL2–CCR2 axis prompts TAM to secrete another chemokine
CCL3, which in turn activates its receptor CCR1 in TAM and promotes lung metastatic seeding in
a breast cancer mouse model [89]. These results suggest that inhibition of CCR1 may have a therapeutic
implication on metastatic progression of certain types of cancer, including CRC and breast cancer.
Some CCR1 inhibitors have been used clinically for patients with rheumatoid arthritis, multiple
sclerosis or chronic obstructive pulmonary disease in phase I/II clinical trials [90,91]. Therefore, it
would be worthwhile to test such CCR1 inhibitors in preventing cancer metastasis, because they have
been already cleared from safety concerns.
6. CCL2 and CCR2
TAM play a key role in the process of colonic tumorigenesis and CRC progression through
production of cyclooxygenase-2 (COX-2) [92]. CCL2, also called monocyte chemotactic protein 1
(MCP-1), is released from CRC and involved in macrophage accumulation and COX-2 expression [93].
CCL2 expression in CRC cells and TAM accumulation are strongly correlated with advanced tumor
stages [32] and a poor prognosis [33]. Expression of CCL2 was also reported as a predictive marker for
liver metastasis of human CRC [33]. The CCL2–CCR2 axis-mediated macrophage recruitment promotes
tumor growth, progression and metastases in breast and prostate cancers [94,95]. In a genetic mouse
model of CRC, inactivation of Ccl2 caused depletion of CCR2+ TAM at the tumor site and reciprocal
accumulation of CTL, which prevented tumor progression [96]. In a mouse model of colitis-associated
carcinogenesis with azoxymethane followed by repetitive administration of dextran sulfate sodium,
depletion of Ccr2 (Ccr2 knockout mice) reduced macrophage infiltration and tumor formation in
the colonic mucosa [97]. In an experimental model of malignant pleural effusion, administration
of a neutralizing antibody against CCL2 could inhibit development of malignant pleural effusion
of CRC [98]. In an orthotopic transplantation mouse model of pancreatic cancer, CCR2 inhibitors
depleted inflammatory monocytes and macrophages, which resulted in decreased tumor growth and
reduced metastasis [99]. As an example of the paradoxical effect of CCL2, it has been reported that
interruption of CCL2 inhibition accelerates breast cancer metastasis through angiogenesis, and that
anti-IL-6 treatment after interruption of anti-CCL2 therapy can prevent lung metastases [100].
In a mouse allograft model, CCR2 is also expressed on CD11b+ Gr1mid myeloid cells, which
promotes liver metastasis of CCL2-expressing CRC cells [34]. Some CD11b+ CCR2+ cells are also found
within the liver metastatic foci obtained from CRC patients, suggesting essentially the same mechanism
can be occurred in the establishment of CRC liver metastasis in humans. Regarding the role of CCR2
on MDSC, it has been reported that CCL2 affects CCR2+ granulocytic-MDSC accumulation and
function in CRC carcinogenesis, and that CCL2 modulates T cell suppression of granulocytic-MDSC in
a STAT3-mediated fashion [35].
While CCR2+ myeloid cells contribute to tumor cell metastasis, CCR2+ endothelium is activated
by CRC-derived CCL2, which increases vascular permeability and cancer cell extravasation through
the JAK2-Stat5 and p38MAPK pathways [36].
7. CCL5 and CCR5
MSC are pluripotent progenitor cells that contribute to the maintenance and regeneration of
a variety of connective tissues [101]. Recent reports have revealed that the bone-marrow-derived
MSC are recruited in large numbers to the stroma of developing tumors [102]. Breast cancer cells
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stimulate CCL5 secretion from MSC, which then acts in a paracrine fashion on the CCR5+ cancer cells
to enhance their motility, invasion and metastasis [8]. In addition to the CCL5–CCR5 axis, hypoxia
induces HIF-dependent CXCL10 secretion from MSC, which recruits CXCR3+ breast cancer cells and
promotes lung metastasis through the CCL10–CXCR3 axis [103]. CXCR3 is also expressed on CRC as
mentioned above, and therefore a similar mechanism may operate in CRC metastasis.
T cell infiltration is often found in CRC tissues and is associated with a good prognosis for CRC
patients [104]. For example, memory and effector-type T cell infiltration in the stroma of CRC is
correlated with negative lymph node metastases, negative distant metastases and negative status
of vessels/perineural invasion, which leads to a prolonged overall survival (OS) and disease-free
survival (DFS) [105]. Moreover, CD8+ CTL infiltration is also found in CRC tissues, which can raise
anti-cancer immunity that prolongs patients’ survival [106]. Most of the CD8+ CTL and type-1 helper
T cells (Th1) at the invasion front of CRC tissues express CCR5, and expression of its ligand CCL5
in the tumor microenvironment is observed predominantly in the stromal CD8+ T lymphocytes at
the invasion front [24], which may accelerate anti-tumor immunity in an autocrine and/or paracrine
manner. Confusingly, another report shows an opposite relationship between CCL5 and CCR5 in the
CRC microenvironment. Namely, CCL5 released from CRC cells recruits CCR5+ T-reg, which leads to
TGF-β-mediated apoptosis of CD8+ CTL and tumor growth by immune escape [37]. Although CCL5
can bind to some chemokine receptors such as CCR1, CCR3 and CCR5, it is unclear which particular
receptor is responsible for the pharmacologic CCL5 neutralization that can suppress cancer progression
in mouse xenograft models [107]. Because these reports on the CCL5–CCR5 axis in the CRC tumor
microenvironment appear to be contradictory, further investigation is awaited to determine whether
the CCL5–CCR5 axis plays a role in anti-tumor immunity or tumor-promotion.
8. CCL20 and CCR6
Accumulation of Th17 lymphocytes in CRC tissues causes poor DFS, while that of Th1
lymphocytes results in prolonged DFS [108]. IL-17 produced from Th17 lymphocytes recruits CD11b+
Gr1+ immature myeloid cells to the tumor site, which induces granulocyte colony-stimulating factor
(G-CSF) to promote tumor resistance to anti-angiogenic therapy (VEGF inhibition) [109]. T-reg also
negatively regulate anti-tumor immunity to facilitate tumor growth, and depletion of total CD4+ T cells
improves tumor immunity with effective tumor rejection [110]. Both Th17 and T-reg express CCR6,
which promotes the migration of these two T cell subsets to the inflammatory site [111]. Moreover,
a subset of IL17+ T-reg is induced from memory CCR6+ T cells [112]. In CRC tissues, the main source
of CCL20, a ligand for CCR6, is considered to be TAM, and CCL20 secreted from TAM recruits CCR6+
T-reg to the tumor site, which synergistically promotes tumor progression in mouse models [43].
In human clinical samples of primary and metastatic CRC, expression of CCR6 and CCL20 is increased
compared with the normal mucosa [113,114]. Both normal colonic epithelial cells and CRC cells
have been demonstrated to bear CCR6 [115]. CCR6 expression in the primary CRC is independently
associated with the presence of synchronous liver metastasis [116]. The serum level of CCL20 is also
reported to be an independent predictive factor for CRC liver metastasis [117]. Recently, it has been
reported that additional knockout of Ccr6 into ApcMin/+ mice, a mouse model of familial adenomatous
polyposis, diminishes the number and size of their intestinal adenomas, suggesting that the intestinal
tumorigenesis driven by the CCL20–CCR6 interaction may be promoted by macrophages recruited
into the intestine [118].
9. CCL19/21 and CCR7
An effective T-cell response for anti-tumor immunity results from the interaction between
antigen-presenting DC and naïve T cells in lymphoid tissues [119]. CCR7 is mainly expressed on
some subsets of CD8+ T lymphocytes, naïve T lymphocytes (CCR7+ CD45RA+) and central memory
T lymphocytes (CCR7+ CD45RA´), which may differentiate into CTL to acquire an anti-tumor
function [44]. Its ligand, CCL19, is expressed from DC that are stimulated by NK cells through
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tumor necrosis factor α (TNF-α) and interferon γ (IFN-γ) [45]. Expression of CCL19 is up-regulated in
lymphoid tissues obtained from CRC patients when treated ex vivo with factors that can stimulate NK
cell function [45]. Expression of CCL19 in human CRC specimens is suppressed when compared with
that in normal intestine [120]. Expression of CCL21, another ligand for CCR7, is also decreased in CRC
tissues [121]. Accordingly, a higher infiltration of CCR7+ T lymphocytes into CRC tissues may predict
prolonged OS and progression-free survival (PFS) [122]. In contrast, some reports show that CCR7
expression on CRC cells themselves plays an important role in cancer progression. CCR7 expression
at the invasion front is strongly correlated with lymph node metastases and decreased OS [123].
When stimulated by CCL21, CCR7 on cancer cells is proposed to regulate MMP-9 and promote lymph
node metastasis [124]. However, another report shows exactly the opposite result that CCR7 expression
on CRC cells prolongs the 3-year survival rate [27]. There are no in vivo studies of mouse models that
show the effect of the CCL19/20–CCR7 blockade on the progression of CRC.
10. CCL24 and CCR3
CCL24 expression is shown to be strongly up-regulated in the biopsy specimens of CRC
liver metastases, as well as in the primary CRC, compared with the adjacent normal tissues [125].
Cancer epithelial cells as well as some of CRC cell lines showed high expression levels of CCL24, and
CCL24 production by CRC cell lines was modulated by Th1/Th2 cytokines. Although little is known
about the interaction of CCL24 with its receptor CCR3 in the tumor microenvironment in vivo, it may
be worth investigating this chemokine axis for its possible role in CRC invasion and metastasis.
11. CX3CL1 and CX3CR1
MSC are also reported to migrate to the CRC microenvironment and differentiate to CAF, which
promotes cancer expansion and metastatic focus formation [126]. One of the attractive explanations
why MSC accumulate to CRC may lie in the CX3CL1–CX3CR1 axis. Expression of CX3CR1 is
up-regulated on MSC when cultured under a hypoxic condition [127]. When co-cultured with
CRC cell line HT29 under hypoxia, the migration ability of MSC increased in vitro. In clinical CRC
specimens, CX3CR1 is expressed on TAM, and CX3CR1 up-regulation in TAM is correlated with a poor
prognosis [46]. Apart from the cell types expressing CX3CR1, Cx3cr1 knockout mice exhibited lower
occurrence of liver metastasis when CRC cells were injected into the liver as allografts. TAM in the
Cx3cr1 knockout mice express significantly less angiogenic markers such as CCR2, VEGFR2, and
CXCR4 compared with wild-type mice, suggesting synergistic effects on macrophage accumulation
between angiogenesis and the CX3CL1–CX3CR1 axis. These results suggest that a blockade of the
CX3CL1–CX3CR1 axis may be an attractive therapeutic target for advanced CRC.
CX3CR1 is also expressed on NK cells and CTL as well as TAM [128]. Because CX3CR1 is
expressed in a wide variety of cell types, it is controversial whether the CX3CL1–CX3CR1 axis is
tumor-suppressive or tumor-promotive. CX3CL1 overexpression in CRC cell lines can reduce their
metastatic potential in a mouse allograft model [129]. CRC patients with higher expression of CX3CL1
were also reported to show a better prognosis [130].
12. Conclusions
Tumor cells not only accumulate genetic mutations in themselves but also affect their surrounding
cells in order to survive in the chaos of the tumor microenvironment. They utilize chemokines in
their armory against the attack from their host. As described in this review, recent studies indicated
that most of the listed chemokines are up-regulated when normal colonic mucosa becomes cancerous
and the cancer becomes more malignant (Figure 1). There are several chemokine inhibitors that are
used in mouse models in vivo, or even in some clinical studies for immune-related diseases. However,
currently, there is no targeted therapy for chemokines to prevent CRC invasion and/or metastasis, as
well as other types of cancer.
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Recently, it was reported that mismatch-repair status of CRC predicted a clinical benefit with the
anti-PD-1 immune checkpoint inhibitor [131]. Mismatch-repair pathway is one of the main causes
of CRC [132], and the study’s results may show the potential advantage of immunotherapy in some
subtypes of CRC. Because chemokine signaling is closely associated with tumor immunity, and tumor
immunotherapy has reached a new milestone with the launch of anti-immune checkpoint therapy such
as anti-PD-1 antibody, effective chemokine-targeted therapy may become within reach in a near future.
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